Baseline demographic and disease characteristics. Data are presented as mean (SD) unless otherwise noted.
| Characteristics | Placebo | Golimumab, 50 mg | Golimumab, 100 mg |
|---|---|---|---|
| Patients, n | 78 | 138 | 140 |
| Male, n (%) | 55 (70.5) | 102 (73.9) | 98 (70.0) |
| Age, yrs | 40.6 ± 12.7 | 39.2 ± 12.5 | 38.6 ± 11.3 |
| Disease duration, yrs | 10.8 ± 10.0 | 7.9 ± 8.1 | 8.1 ± 8.3 |
| CRP, mg/dl | 1.9 ± 2.3 | 1.8 ± 1.8 | 1.8 ± 2.1 |
| Patient assessment of disease activity (0–10 cm) | 7.2 ± 1.7 | 6.8 ± 1.8a | 7.0 ± 1.9 |
| Patient assessment of total back pain (0–10 cm) | 7.5 ± 1.6 | 7.1 ± 1.5a | 7.6 ± 1.6 |
| ASDAS | 3.9 ± 0.8 | 3.8 ± 0.8a | 4.0 ± 0.8 |
| < 1.3, n (%) | 0 (0) | 0 (0) | 0 (0) |
| 1.3 to < 2.1, n (%) | 0 (0) | 1 (0.7) | 0 (0) |
| 2.1–3.5, n (%) | 27 (34.6) | 49 (35.8) | 50 (35.7) |
| > 3.5, n (%) | 51 (65.4) | 87 (63.5) | 90 (64.3) |
| BASDAI, 0–10 | 6.6 ± 1.5 | 6.5 ± 1.6 | 6.9 ± 1.5 |
| BASFI, 0–10 | 5.1 ± 2.3b | 5.0 ± 2.4 | 5.2 ± 2.6 |
| SF-36 | |||
| PCS, 0–100 | 29.2 ± 7.1 | 29.3 ± 8.3 | 30.7 ± 8.1c |
| MCS, 0–100 | 45.7 ± 10.7 | 45.1 ± 10.5 | 42.9 ± 11.5c |
↵a n = 137.
↵b n = 76.
↵c n = 139. CRP: C-reactive protein; ASDAS: Ankylosing Spondylitis Disease Activity Score; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index; SF-36 PCS/MCS: 36-item Medical Outcomes Study Short Form-36 physical/mental component summary.